{"protocolSection":{"identificationModule":{"nctId":"NCT04725188","orgStudyIdInfo":{"id":"7684A-002"},"secondaryIdInfos":[{"id":"MK-7684A-002","type":"OTHER","domain":"MSD"},{"id":"KEYVIBE-002","type":"OTHER","domain":"MSD"},{"id":"2022-501252-28-00","type":"REGISTRY","domain":"EU CT"},{"id":"U1111-1275-8661","type":"REGISTRY","domain":"UTN"},{"id":"2020-004034-38","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Pembrolizumab/Vibostolimab Coformulation (MK-7684A) or Pembrolizumab/Vibostolimab Coformulation Plus Docetaxel Versus Docetaxel for Metastatic Non Small Cell Lung Cancer (NSCLC) With Progressive Disease After Platinum Doublet Chemotherapy and Immunotherapy (MK-7684A-002, KEYVIBE-002)","officialTitle":"A Phase 2, Multicenter, Randomized Study to Compare the Efficacy and Safety of MK-7684A or MK-7684A Plus Docetaxel Versus Docetaxel Monotherapy in the Treatment of Participants With Metastatic Non-small Cell Lung Cancer With Progressive Disease After Treatment With a Platinum Doublet Chemotherapy and Immunotherapy"},"statusModule":{"statusVerifiedDate":"2025-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-04-20","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2023-01-26","type":"ACTUAL"},"completionDateStruct":{"date":"2024-10-17","type":"ACTUAL"},"studyFirstSubmitDate":"2021-01-25","studyFirstSubmitQcDate":"2021-01-25","studyFirstPostDateStruct":{"date":"2021-01-26","type":"ACTUAL"},"resultsFirstSubmitDate":"2024-01-19","resultsFirstSubmitQcDate":"2024-03-05","resultsFirstPostDateStruct":{"date":"2024-04-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-07-30","lastUpdatePostDateStruct":{"date":"2025-08-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The main purpose of this study is to compare pembrolizumab/vibostolimab coformulation (MK-7684A) plus docetaxel or pembrolizumab/vibostolimab coformulation to normal saline placebo plus docetaxel. Participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti- programmed cell death 1 (PD-1)/ programmed cell death ligand 1(PD-L1) monoclonal antibody (mAb). MK-7684A is a coformulation product of pembrolizumab/vibostolimab. The dual primary hypotheses of the study are pembrolizumab/vibostolimab coformulation plus docetaxel and pembrolizumab/vibostolimab coformulation is superior to normal saline placebo plus docetaxel with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).","detailedDescription":"Participants may receive additional 17 cycles of pembrolizumab/vibostolimab (each cycle length = 21 days) for an additional 1 year of treatment as second course phase at investigator's discretion."},"conditionsModule":{"conditions":["Metastatic Non Small Cell Lung Cancer"],"keywords":["Programmed Cell Death Receptor 1 (PD-1)","Programmed Cell Death Receptor Ligand 1 (PD-L1)","Programmed Cell Death Receptor Ligand 2 (PD-L2)","PD-1","PDL1","PD-L1","PD-L2"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Arm 1 and Arm 3: Double-blind with in-house blinding Arm 2: Unblinded Open-label","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":255,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel","type":"EXPERIMENTAL","description":"Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle will be 21 days.","interventionNames":["Biological: Pembrolizumab/Vibostolimab coformulation","Drug: Docetaxel"]},{"label":"Arm 2: Pembrolizumab/Vibostolimab coformulation","type":"EXPERIMENTAL","description":"Participants receive pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle will be 21 days.","interventionNames":["Biological: Pembrolizumab/Vibostolimab coformulation"]},{"label":"Arm 3: Placebo + Docetaxel","type":"ACTIVE_COMPARATOR","description":"Participants receive normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 IV infusion Q3W. Each cycle will be 21 days.","interventionNames":["Drug: Docetaxel","Drug: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Pembrolizumab/Vibostolimab coformulation","description":"Pembrolizumab 200 mg + vibostolimab 200 mg/20 mL vial IV infusion Q3W up to approximately 2 years.","armGroupLabels":["Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel","Arm 2: Pembrolizumab/Vibostolimab coformulation"],"otherNames":["MK-7684A"]},{"type":"DRUG","name":"Docetaxel","description":"Docetaxel 75 mg\\^m2 IV infusion Q3W until discontinuation due to progressive disease or unacceptable toxicity. Docetaxel will serve as part of an experimental treatment in Arm 1, and as an active comparator in Arm 3.","armGroupLabels":["Arm 1: Pembrolizumab/Vibostolimab coformulation + Docetaxel","Arm 3: Placebo + Docetaxel"],"otherNames":["Taxotere"]},{"type":"DRUG","name":"Placebo","description":"Normal saline IV infusion Q3W up to approximately 2 years","armGroupLabels":["Arm 3: Placebo + Docetaxel"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment","description":"PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.","timeFrame":"Up to approximately 21 months"}],"secondaryOutcomes":[{"measure":"Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment","description":"ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.","timeFrame":"Up to approximately 21 months"},{"measure":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the date of death due to any cause.","timeFrame":"Up to approximately 21 months"},{"measure":"Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment","description":"For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.","timeFrame":"Up to approximately 21 months"},{"measure":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.","timeFrame":"Up to approximately 39 months"},{"measure":"Number of Participants Who Discontinued Study Treatment Due to an AE","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.","timeFrame":"Up to approximately 27 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)\n* Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or reactive oxygen species (ROS) 1 directed therapy is not indicated as primary therapy\n* Has progressive disease (PD) on treatment with one prior anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) monoclonal antibody (mAb) administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies\n\n  * Retreatment with the same anti-PD-L1/PD-L1 mAb is acceptable in the overall course of treatment\n* Has PD as determined by the investigator after platinum doublet chemotherapy for metastatic disease\n* Has measurable disease defined as at least 1 measurable lesion by computed tomography (CT) or magnetic resonance imaging (MRI), based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)\n* Has provided tumor tissue for PD-L1 biomarker analysis from an archival sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated\n* Has a life expectancy of at least 3 months\n* Has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1 assessed within 7 days prior to randomization\n* Male participants randomized to docetaxel are eligible to participant if they agree to refrain from donating sperm, and either 1) be abstinent from heterosexual intercourse; or 2) must agree to follow contraceptive guidance as per study protocol unless confirmed to be azoospermic during the intervention period and for at least 180 days after the last dose of docetaxel\n* Female participants must be not pregnant, not breastfeeding, and not be a woman of child-bearing potential (WOCBP). A WOCBP is eligible is she agrees to either use contraception, or be abstinent from heterosexual intercourse during the intervention period and for ≥120 days after the last dose of study intervention. If a WOCBP is randomized to docetaxel, she agrees not to donate eggs and either uses contraception or be abstinent from heterosexual intercourse during the treatment period and for ≥180 days after the last dose of docetaxel\n* Has adequate organ function\n\nExclusion Criteria:\n\n* Has known active or untreated central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has a known history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for at least 3 years since initiation of that therapy\n* Has received docetaxel as monotherapy or in combination with other therapies\n* Has received previous treatment with another agent targeting the T-cell immunoreceptor with immunoglobulin \\[Ig\\] and immunoreceptor tyrosine-based inhibitory motif \\[ITIM\\] domains (TIGIT) pathway\n* Has received radiotherapy within 2 weeks of start of study intervention. One week washout is permitted for palliative radiation to non-CNS disease\n* Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks before the first dose of study intervention\n* Has severe hypersensitivity (≥Grade 3) to docetaxel or pembrolizumab/vibostolimab coformulation and/or any of its excipients\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days before the first dose of study intervention\n* Has interstitial lung disease, or history of pneumonitis requiring steroids for treatment\n* Has known history of active human immunodeficiency virus (HIV), Hepatitis B or Hepatitis C\n* Has had an allogenic tissue/solid organ transplant\n* Has a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Cedars-Sinai Medical Center ( Site 2522)","city":"Los Angeles","state":"California","zip":"90048","country":"United States","geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"Illinois Cancer Care ( Site 2534)","city":"Peoria","state":"Illinois","zip":"61615","country":"United States","geoPoint":{"lat":40.69365,"lon":-89.58899}},{"facility":"Baptist Health Lexington-Research ( Site 2502)","city":"Lexington","state":"Kentucky","zip":"40503","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"University of Maryland ( Site 2528)","city":"Baltimore","state":"Maryland","zip":"21201","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Hattiesburg Clinic Hematology/Oncology ( Site 2511)","city":"Hattiesburg","state":"Mississippi","zip":"39401","country":"United States","geoPoint":{"lat":31.32712,"lon":-89.29034}},{"facility":"Mercy Research - Cancer and Hematology Center ( Site 2535)","city":"Springfield","state":"Missouri","zip":"65804","country":"United States","geoPoint":{"lat":37.21533,"lon":-93.29824}},{"facility":"Mercy Research - David C. Pratt Cancer Center ( Site 2532)","city":"St Louis","state":"Missouri","zip":"63109","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Montefiore- Einstein Center for Cancer Care-Oncology ( Site 2509)","city":"The Bronx","state":"New York","zip":"10461","country":"United States","geoPoint":{"lat":40.84985,"lon":-73.86641}},{"facility":"University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 2526)","city":"Cincinnati","state":"Ohio","zip":"45219","country":"United States","geoPoint":{"lat":39.12711,"lon":-84.51439}},{"facility":"St Francis Cancer Center-Research Office ( Site 2531)","city":"Greenville","state":"South Carolina","zip":"29607","country":"United States","geoPoint":{"lat":34.85262,"lon":-82.39401}},{"facility":"Centro de Oncología e Investigación de Buenos Aires ( Site 0008)","city":"Berazategui","state":"Buenos Aires","zip":"B1884BBF","country":"Argentina","geoPoint":{"lat":-34.76531,"lon":-58.21278}},{"facility":"Hospital Privado de Comunidad ( Site 0004)","city":"Mar del Plata","state":"Buenos Aires","zip":"7600","country":"Argentina","geoPoint":{"lat":-38.00042,"lon":-57.5562}},{"facility":"Instituto de Investigaciones Clínicas Mar del Plata ( Site 0002)","city":"Mar del Plata","state":"Buenos Aires","zip":"7600","country":"Argentina","geoPoint":{"lat":-38.00042,"lon":-57.5562}},{"facility":"Instituto de Oncología de Rosario ( Site 0003)","city":"Rosario","state":"Santa Fe Province","zip":"S2000KZE","country":"Argentina","geoPoint":{"lat":-32.94682,"lon":-60.63932}},{"facility":"Hospital Privado Universitario de Córdoba ( Site 0001)","city":"Córdoba","zip":"5016","country":"Argentina","geoPoint":{"lat":-31.40648,"lon":-64.18853}},{"facility":"Fundación CORI para la Investigación y Prevención del Cáncer ( Site 0005)","city":"La Rioja","zip":"F5300COE","country":"Argentina","geoPoint":{"lat":-29.41328,"lon":-66.85637}},{"facility":"Canberra Hospital ( Site 0104)","city":"Canberra","state":"Australian Capital Territory","zip":"2605","country":"Australia","geoPoint":{"lat":-35.28346,"lon":149.12807}},{"facility":"Gold Coast University Hospital-Clinical Trials Service ( Site 0106)","city":"Southport","state":"Queensland","zip":"4215","country":"Australia","geoPoint":{"lat":-27.96724,"lon":153.39796}},{"facility":"Fiona Stanley Hospital-Medical Oncology ( Site 0102)","city":"Murdoch","state":"Western Australia","zip":"6150","country":"Australia","geoPoint":{"lat":-32.06987,"lon":115.83757}},{"facility":"Medizinische Universität Graz ( Site 0201)","city":"Graz","state":"Styria","zip":"8036","country":"Austria","geoPoint":{"lat":47.06733,"lon":15.44197}},{"facility":"Ordensklinikum Linz GmbH Elisabethinen-Department of Pneumology ( Site 0203)","city":"Linz","state":"Upper Austria","zip":"4020","country":"Austria","geoPoint":{"lat":48.30639,"lon":14.28611}},{"facility":"Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 0204)","city":"Vienna","zip":"1210","country":"Austria","geoPoint":{"lat":48.20849,"lon":16.37208}},{"facility":"AZ Sint-Maarten, Campus Leopoldstraat 2 ( Site 0333)","city":"Mechelen","state":"Antwerpen","zip":"2800","country":"Belgium","geoPoint":{"lat":51.02574,"lon":4.47762}},{"facility":"UZ Brussel ( Site 0336)","city":"Brussels","state":"Bruxelles-Capitale, Region de","zip":"1090","country":"Belgium","geoPoint":{"lat":50.85045,"lon":4.34878}},{"facility":"Grand Hôpital de Charleroi-Oncology & Hematology ( Site 0337)","city":"Charleroi","state":"Hainaut","zip":"6000","country":"Belgium","geoPoint":{"lat":50.41136,"lon":4.44448}},{"facility":"Jessa Ziekenhuis-Pulmonology & Thoracic Oncology ( Site 0338)","city":"Hasselt","state":"Limburg","zip":"3500","country":"Belgium","geoPoint":{"lat":50.93106,"lon":5.33781}},{"facility":"AZ Nikolaas ( Site 0334)","city":"Sint-Niklaas","state":"Oost-Vlaanderen","zip":"1932","country":"Belgium","geoPoint":{"lat":51.16509,"lon":4.1437}},{"facility":"Hospital Nossa Senhora da Conceição ( Site 0403)","city":"Porto Alegre","state":"Rio Grande do Sul","zip":"91350-200","country":"Brazil","geoPoint":{"lat":-30.03283,"lon":-51.23019}},{"facility":"ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0400)","city":"São Paulo","state":"São Paulo","zip":"01246-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Centro de Tratamento de Tumores Botafogo - CTTB-Pesquisa Clínica ( Site 0402)","city":"Rio de Janeiro","zip":"22250-905","country":"Brazil","geoPoint":{"lat":-22.90642,"lon":-43.18223}},{"facility":"Hospital Paulistano ( Site 0406)","city":"São Paulo","zip":"01321-000","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Rigshospitalet ( Site 0702)","city":"Copenhagen","state":"Capital Region","zip":"2100","country":"Denmark","geoPoint":{"lat":55.67594,"lon":12.56553}},{"facility":"Odense Universitetshospital ( Site 0700)","city":"Odense","state":"Region Syddanmark","zip":"5000","country":"Denmark","geoPoint":{"lat":55.39594,"lon":10.38831}},{"facility":"Sygehus Soenderjylland-Kraeftambulatoriet ( Site 0705)","city":"Sønderborg","state":"Region Syddanmark","zip":"6400","country":"Denmark","geoPoint":{"lat":54.90896,"lon":9.78917}},{"facility":"Oulun yliopistollinen sairaala ( Site 0902)","city":"Oulu","state":"North Ostrobothnia","zip":"90220","country":"Finland","geoPoint":{"lat":65.01236,"lon":25.46816}},{"facility":"Tampereen yliopistollinen sairaala-Oncology ( Site 0906)","city":"Tampere","state":"Pirkanmaa","zip":"33520","country":"Finland","geoPoint":{"lat":61.49911,"lon":23.78712}},{"facility":"Vaasan Keskussairaala ( Site 0903)","city":"Vaasa","state":"Pohjanmaa","zip":"65130","country":"Finland","geoPoint":{"lat":63.096,"lon":21.61577}},{"facility":"Turku University Hospital-The Department of Pulmonary Medicine ( Site 0905)","city":"Turku","state":"Southwest Finland","zip":"20520","country":"Finland","geoPoint":{"lat":60.45148,"lon":22.26869}},{"facility":"Nouvel Hôpital Civil (NHC) ( Site 1000)","city":"Strasbourg","state":"Alsace","zip":"67000","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"facility":"Institut Bergonié - Centre Régional de Lutte Contre Le Cance-Medical Oncology ( Site 1009)","city":"Bordeaux","state":"Aquitaine","zip":"33000","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"facility":"Centre Hospitalier Universitaire de Caen - Hôpital Côte de Nacre ( Site 1006)","city":"Caen","state":"Calvados","zip":"14033","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"facility":"CHU de Toulouse - Hopital Larrey-service de pneumologie ( Site 1008)","city":"Toulouse","state":"Haute-Garonne","zip":"31059","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"Clinique Ambroise Paré ( Site 1007)","city":"Beuvry","state":"Pas-de-Calais","zip":"62660","country":"France","geoPoint":{"lat":50.51674,"lon":2.68541}},{"facility":"Centre Hospitalier du Mans ( Site 1002)","city":"Le Mans","state":"Sarthe","zip":"72037","country":"France","geoPoint":{"lat":48.0021,"lon":0.20251}},{"facility":"Gustave Roussy ( Site 1005)","city":"Villejuif","state":"Val-de-Marne","zip":"94800","country":"France","geoPoint":{"lat":48.7939,"lon":2.35992}},{"facility":"HIA Sainte Anne ( Site 1003)","city":"Toulon","state":"Var","zip":"83800 Cedex 9","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"facility":"Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1004)","city":"Avignon","state":"Vaucluse","zip":"84000","country":"France","geoPoint":{"lat":43.94834,"lon":4.80892}},{"facility":"Onkologie Ravensburg ( Site 1104)","city":"Ravensburg","state":"Baden-Wurttemberg","zip":"88212","country":"Germany","geoPoint":{"lat":47.78198,"lon":9.61062}},{"facility":"Klinikverbund Allgaeu gGmbH ( Site 1109)","city":"Immenstadt im Allgäu","state":"Bavaria","zip":"87509","country":"Germany","geoPoint":{"lat":47.55996,"lon":10.21394}},{"facility":"Helios Dr. Horst Schmidt Kliniken ( Site 1108)","city":"Wiesbaden","state":"Hesse","zip":"65199","country":"Germany","geoPoint":{"lat":50.08601,"lon":8.24435}},{"facility":"Universitätsklinikum Bonn ( Site 1111)","city":"Bonn","state":"North Rhine-Westphalia","zip":"53127","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"Helios Klinikum Emil von Behring Berlin-Zehlendorf ( Site 1106)","city":"Berlin","zip":"14165","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Soroka Medical Center ( Site 1202)","city":"Beersheba","zip":"8410101","country":"Israel","geoPoint":{"lat":31.25181,"lon":34.7913}},{"facility":"Rambam Health Care Campus-Oncology ( Site 1203)","city":"Haifa","zip":"3109601","country":"Israel","geoPoint":{"lat":32.81303,"lon":34.99928}},{"facility":"Shaare Zedek Medical Center-Oncology ( Site 1206)","city":"Jerusalem","zip":"9103102","country":"Israel","geoPoint":{"lat":31.76904,"lon":35.21633}},{"facility":"Sourasky Medical Center ( Site 1205)","city":"Tel Aviv","zip":"6423906","country":"Israel","geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Azienda Ospedaliera S. Giovanni Addolorata-Oncologia Medica ( Site 1307)","city":"Rome","state":"Lazio","zip":"00184","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"facility":"Azienda Ospedaliera Dei Colli-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1308)","city":"Naples","state":"Napoli","zip":"80131","country":"Italy","geoPoint":{"lat":40.85216,"lon":14.26811}},{"facility":"CRO-IRCCS-medical oncology ( Site 1304)","city":"Aviano","state":"Pordenone","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"facility":"Azienda Sanitaria Ospedaliera S Luigi Gonzaga-Oncologia Polmonare ( Site 1300)","city":"Orbassano","state":"Torino","zip":"10043","country":"Italy","geoPoint":{"lat":45.00547,"lon":7.53813}},{"facility":"Azienda Ospedaliera Universitaria Careggi-SOD ONCOLOGIA MEDICA ( Site 1306)","city":"Florence","state":"Tuscany","zip":"50134","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"Ospedale San Raffaele-Oncologia Medica ( Site 1305)","city":"Milan","zip":"20132","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1301)","city":"Milan","zip":"20141","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Fondazione Policlinico Universitario Agostino Gemelli-Medical Oncology ( Site 1303)","city":"Roma","zip":"00168","country":"Italy","geoPoint":{"lat":44.99364,"lon":11.10642}},{"facility":"Hospital Sultan Ismail ( Site 1503)","city":"Johor Bahru","state":"Johor","zip":"81100","country":"Malaysia","geoPoint":{"lat":1.4655,"lon":103.7578}},{"facility":"University Malaya Medical Centre ( Site 1501)","city":"Lembah Pantai","state":"Kuala Lumpur","zip":"59100","country":"Malaysia"},{"facility":"Hospital Tengku Ampuan Afzan ( Site 1500)","city":"Kuantan","state":"Pahang","zip":"25100","country":"Malaysia","geoPoint":{"lat":3.8077,"lon":103.326}},{"facility":"Beacon Hospital Sdn Bhd ( Site 1504)","city":"Petaling Jaya","state":"Selangor","zip":"46050","country":"Malaysia","geoPoint":{"lat":3.10726,"lon":101.60671}},{"facility":"Przychodnia Lekarska KOMED ( Site 1704)","city":"Konin","state":"Greater Poland Voivodeship","zip":"62-500","country":"Poland","geoPoint":{"lat":52.22338,"lon":18.25121}},{"facility":"Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier","city":"Warsaw","state":"Masovian Voivodeship","zip":"02-781","country":"Poland","geoPoint":{"lat":52.22977,"lon":21.01178}},{"facility":"Saint Petersburg State University-Clinic of advanced medical technologies n. a. Nicolay I. Pirogov (","city":"Saint Petersburg","state":"Leningradskaya Oblast'","zip":"190020","country":"Russia"},{"facility":"Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 1911)","city":"Saint Petersburg","state":"Leningradskaya Oblast'","zip":"198255","country":"Russia"},{"facility":"Moscow Clinical Research Center-Chemotherapy department ( Site 1910)","city":"Moscow","state":"Moscow","zip":"111123","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Central Clinical Hospital of the Presidential Administrative Department ( Site 1902)","city":"Moscow","state":"Moscow","zip":"121359","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"facility":"Hadassah Medical-Oncology department ( Site 1912)","city":"Moscow","state":"Moscow Oblast","zip":"121205","country":"Russia"},{"facility":"Nizhegorodsky Regional Oncology Dispensary, Branch #2-chemotherapy ( Site 1909)","city":"Nizhny Novgorod","state":"Nizhny Novgorod Oblast","zip":"603081","country":"Russia","geoPoint":{"lat":56.32867,"lon":44.00205}},{"facility":"Budgetary Healthcare Institution of Omsk Region Clinical Oncology Dispensary ( Site 1908)","city":"Omsk","state":"Omsk Oblast","zip":"644013","country":"Russia","geoPoint":{"lat":54.99244,"lon":73.36859}},{"facility":"GBUZ LOKB-Oncology department #1 ( Site 1905)","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"194291","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S","city":"Saint Petersburg","state":"Sankt-Peterburg","zip":"197758","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"facility":"Seoul National University Bundang Hospital ( Site 2003)","city":"Seongnam","state":"Kyonggi-do","zip":"13620","country":"South Korea","geoPoint":{"lat":35.54127,"lon":127.39683}},{"facility":"The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 2005)","city":"Suwon","state":"Kyonggi-do","zip":"16247","country":"South Korea","geoPoint":{"lat":37.29111,"lon":127.00889}},{"facility":"Chungbuk National University Hospital-Internal medicine ( Site 2004)","city":"Cheongju-si","state":"North Chungcheong","zip":"28644","country":"South Korea","geoPoint":{"lat":36.63722,"lon":127.48972}},{"facility":"Asan Medical Center-Oncology ( Site 2000)","city":"Songpagu","state":"Seoul","zip":"05505","country":"South Korea"},{"facility":"HOSPITAL CLÍNIC DE BARCELONA-ICHMO- Clinic Institut of Haematological and Oncological diseases ( Sit","city":"Barcelona","state":"Catalonia","zip":"08036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital de la Santa Creu i Sant Pau-Oncología Médica ( Site 2102)","city":"Barcelona","state":"Catalonia","zip":"08041","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2101)","city":"Madrid","zip":"28009","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Hospital Universitario Virgen de Valme-Departamento de Oncologia ( Site 2103)","city":"Seville","zip":"41014","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Ospedale Regionale Bellinzona e Valli ( Site 2203)","city":"Bellinzona","state":"Canton Ticino","zip":"6500","country":"Switzerland","geoPoint":{"lat":46.19278,"lon":9.01703}},{"facility":"Chang Gung Memorial Hospital at Kaohsiung ( Site 2303)","city":"Kaohsiung Niao Sung Dist","state":"Kaohsiung","zip":"83301","country":"Taiwan"},{"facility":"Taichung Veterans General Hospital-Chest ( Site 2307)","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"NATIONAL CHENG-KUNG UNI. HOSP.-clinical trial center ( Site 2302)","city":"Tainan","zip":"704","country":"Taiwan","geoPoint":{"lat":22.99083,"lon":120.21333}},{"facility":"National Taiwan University Hospital-Oncology ( Site 2304)","city":"Taipei","zip":"10002","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Mackay Memorial Hospital-Chest Medicine ( Site 2305)","city":"Taipei","zip":"10449","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Chulalongkorn University ( Site 2403)","city":"Bangkok","state":"Bangkok","zip":"10330","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}},{"facility":"Faculty of Medicine Siriraj Hospital ( Site 2400)","city":"Bangkok","state":"Bangkok","zip":"10700","country":"Thailand","geoPoint":{"lat":13.75398,"lon":100.50144}}]},"referencesModule":{"seeAlsoLinks":[{"label":"Merck Clinical Trials Information","url":"https://www.merckclinicaltrials.com/"},{"label":"Plain Language Summary","url":"https://msd.trialsummaries.com/Study/StudyDetails?id=26206&tenant=MT_MSD_9011"}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"FG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"FG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"85"}]},{"type":"Treated","achievements":[{"groupId":"FG000","numSubjects":"85"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"83"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"87"},{"groupId":"FG001","numSubjects":"83"},{"groupId":"FG002","numSubjects":"85"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"72"},{"groupId":"FG001","numSubjects":"69"},{"groupId":"FG002","numSubjects":"76"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"1"}]},{"type":"Sponsor Decision","reasons":[{"groupId":"FG000","numSubjects":"12"},{"groupId":"FG001","numSubjects":"12"},{"groupId":"FG002","numSubjects":"7"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"BG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"BG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"BG003","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"83"},{"groupId":"BG002","value":"85"},{"groupId":"BG003","value":"255"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"64.7","spread":"8.8"},{"groupId":"BG001","value":"66.0","spread":"7.4"},{"groupId":"BG002","value":"65.8","spread":"8.0"},{"groupId":"BG003","value":"65.5","spread":"8.1"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"24"},{"groupId":"BG003","value":"74"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"61"},{"groupId":"BG003","value":"181"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"12"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"27"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"68"},{"groupId":"BG002","value":"65"},{"groupId":"BG003","value":"195"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"6"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"33"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"11"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"10"},{"groupId":"BG003","value":"35"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"2"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"62"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"185"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"14"},{"groupId":"BG003","value":"32"}]}]}]},{"title":"Programmed Cell Death Ligand 1 (PD-L1) Status at Baseline","description":"Participants were assessed for their PD-L1 tumor expression level by immunohistochemistry assay using tumor tissue from a biopsy. Randomization of participants in the study was stratified by PD-L1 tumor proportion score (TPS) at baseline (\\<1%, 1-49%, or ≥ 50%). Higher percentages of PD-L1 TPS staining correspond to higher positivity of PD-L1 on a tumor. Participants were classified as follows: \\<1% = PD-L1 negative, 1-49% = PD-L1 weakly positive; and ≥50% = PD-L1 strongly positive.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Tumor proportion score (TPS) ≥50%","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"14"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"42"}]},{"title":"TPS 1-49%","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"35"},{"groupId":"BG003","value":"88"}]},{"title":"TPS <1%","measurements":[{"groupId":"BG000","value":"37"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"116"}]},{"title":"Unknown (Not evaluable due to <100 viable tumor cells)","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"5"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"9"}]}]}]},{"title":"Predominant Tumor Histology","description":"Participants were classified according to tumor histology: Squamous or Non-squamous.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Squamous","measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"34"},{"groupId":"BG003","value":"80"}]},{"title":"Non-squamous","measurements":[{"groupId":"BG000","value":"61"},{"groupId":"BG001","value":"63"},{"groupId":"BG002","value":"51"},{"groupId":"BG003","value":"175"}]}]}]},{"title":"Prior Lines of Therapy","description":"Participants were classified according to the number of prior lines of therapy they received to treat their metastatic Non Small Cell Lung Cancer (NSCLC): 1, 2, 3, 4, or ≥5.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"1","measurements":[{"groupId":"BG000","value":"58"},{"groupId":"BG001","value":"49"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"159"}]},{"title":"2","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"28"},{"groupId":"BG002","value":"26"},{"groupId":"BG003","value":"79"}]},{"title":"3","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"7"},{"groupId":"BG003","value":"12"}]},{"title":"4","measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"3"}]},{"title":"≥5","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"2"}]}]}]},{"title":"Sequence of Prior Anti-Programmed Cell Death Receptor 1 (PD-1)/PD-L1","description":"Participants were stratified by the timing of prior Anti-PD-1/PD-L1 therapy: immediate prior therapy versus not immediate prior therapy.","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Immediate Prior Therapy","measurements":[{"groupId":"BG000","value":"72"},{"groupId":"BG001","value":"70"},{"groupId":"BG002","value":"72"},{"groupId":"BG003","value":"214"}]},{"title":"Not the Immediate Prior Therapy","measurements":[{"groupId":"BG000","value":"15"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"41"}]}]}]},{"title":"Eastern Cooperative Oncology Group (ECOG) Performance Status","description":"Randomization of participants in the study was stratified by an ECOG Performance Status of 0 (Fully active, able to carry on all pre-disease performance without restriction) or 1 (Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature).","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"ECOG = 0","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"32"},{"groupId":"BG003","value":"96"}]},{"title":"ECOG = 1","measurements":[{"groupId":"BG000","value":"53"},{"groupId":"BG001","value":"53"},{"groupId":"BG002","value":"53"},{"groupId":"BG003","value":"159"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) Assessment","description":"PFS is defined as the time from randomization to the first documented disease progression (PD) or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by BICR is presented.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 21 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"85"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"3.9","upperLimit":"6.8"},{"groupId":"OG001","value":"2.7","lowerLimit":"1.8","upperLimit":"4.0"},{"groupId":"OG002","value":"3.2","lowerLimit":"2.8","upperLimit":"5.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0910","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.77","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.53","ciUpperLimit":"1.13"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9622","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"1.40","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.96","ciUpperLimit":"2.02"}]},{"type":"SECONDARY","title":"Objective Response Rate (ORR) Per RECIST 1.1 by BICR Assessment","description":"ORR is defined as the percentage of participants who have a confirmed complete response (CR: Disappearance of all target lesions) or a partial response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1. The percentage of participants who experience a CR or PR as assessed by BICR based on RECIST 1.1 is presented.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"Percentage of participants","timeFrame":"Up to approximately 21 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"85"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","lowerLimit":"20.5","upperLimit":"40.6"},{"groupId":"OG001","value":"6.0","lowerLimit":"2.0","upperLimit":"13.5"},{"groupId":"OG002","value":"15.3","lowerLimit":"8.4","upperLimit":"24.7"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0113","statisticalMethod":"Miettinen & Nurminen method","paramType":"Difference in percentage","paramValue":"14.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"2.1","ciUpperLimit":"26.9"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.9750","statisticalMethod":"Miettinen & Nurminen method","paramType":"Difference in percentage","paramValue":"-9.4","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"-19.6","ciUpperLimit":"0.0"}]},{"type":"SECONDARY","title":"Overall Survival (OS)","description":"OS is defined as the time from randomization to the date of death due to any cause.","populationDescription":"All randomized participants","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 21 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"87"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"85"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.2","lowerLimit":"8.6","upperLimit":"14.9"},{"groupId":"OG001","value":"7.5","lowerLimit":"5.2","upperLimit":"13.4"},{"groupId":"OG002","value":"8.8","lowerLimit":"6.4","upperLimit":"11.1"}]}]}],"analyses":[{"groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0943","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"0.76","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.50","ciUpperLimit":"1.15"},{"groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5974","statisticalMethod":"Regression, Cox","paramType":"Hazard Ratio (HR)","paramValue":"1.05","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.70","ciUpperLimit":"1.58"}]},{"type":"SECONDARY","title":"Duration of Response (DOR) Per RECIST 1.1 by BICR Assessment","description":"For participants who demonstrate a confirmed CR (Disappearance of all target lesions) or confirmed PR (At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1, DOR is defined as the time from first documented evidence of CR or PR until disease progression (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also have demonstrated an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed by BICR is presented.","populationDescription":"All randomized participants who demonstrated a confirmed CR or PR","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to approximately 21 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.5","lowerLimit":"5.3","upperLimit":"10.7"},{"groupId":"OG001","value":"NA","lowerLimit":"2.8","upperLimit":"NA","comment":"NA=Median DOR not reached at time of data cutoff due to insufficient number of responding participants with relapse\n\nNA=DOR upper limit not reached at time of data cutoff due to insufficient number of responding participants with relapse"},{"groupId":"OG002","value":"NA","lowerLimit":"3.0","upperLimit":"NA","comment":"NA = Median DOR not reached at time of data cutoff due to insufficient number of responding participants with relapse\n\nNA=DOR upper limit not reached at time of data cutoff due to insufficient number of responding participants with relapse"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Experienced an Adverse Event (AE)","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experienced an AE is reported here.","populationDescription":"Per protocol, the safety analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants are included in the treatment group corresponding to the study treatment they actually received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 39 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"76"},{"groupId":"OG002","value":"82"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Discontinued Study Treatment Due to an AE","description":"An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinued study treatment due to an AE is reported here.","populationDescription":"Per protocol, the safety analysis population consisted of all randomized participants who received at least 1 dose of study treatment. Participants are included in the treatment group corresponding to the study treatment they actually received.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to approximately 27 months","groups":[{"id":"OG000","title":"Arm 1: Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."},{"id":"OG001","title":"Arm 2: Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days."},{"id":"OG002","title":"Arm 3: Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"85"},{"groupId":"OG001","value":"83"},{"groupId":"OG002","value":"83"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"24"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to approximately 39 months","description":"All-cause mortality included all randomized participants. Serious and other AEs included all randomized participants who received at least 1 dose of study treatment. Per protocol, disease progression of cancer under study was not considered an AE unless considered related to study treatment. Thus, MedDRA preferred terms \"Neoplasm progression\", \"Malignant neoplasm progression\" \\& \"Disease progression\" not related to study treatment are excluded as AEs. Data are reported by treatment received.","eventGroups":[{"id":"EG000","title":"Pembrolizumab/Vibostolimab Coformulation + Docetaxel","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via intravenous (IV) infusion once every 3 weeks (Q3W) for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days.","deathsNumAffected":74,"deathsNumAtRisk":87,"seriousNumAffected":48,"seriousNumAtRisk":85,"otherNumAffected":83,"otherNumAtRisk":85},{"id":"EG001","title":"Pembrolizumab/Vibostolimab Coformulation","description":"Participants received pembrolizumab/vibostolimab (coformulation of 200 mg pembrolizumab and 200 mg vibostolimab) via IV infusion Q3W for up to 35 cycles up to approximately 2 years. Each cycle was 21 days.","deathsNumAffected":70,"deathsNumAtRisk":83,"seriousNumAffected":26,"seriousNumAtRisk":83,"otherNumAffected":67,"otherNumAtRisk":83},{"id":"EG002","title":"Placebo + Docetaxel","description":"Participants received normal saline placebo via IV infusion Q3W for up to 35 cycles up to approximately 2 years plus docetaxel 75 mg/m\\^2 via IV infusion Q3W. Each cycle was 21 days.","deathsNumAffected":77,"deathsNumAtRisk":85,"seriousNumAffected":37,"seriousNumAtRisk":83,"otherNumAffected":76,"otherNumAtRisk":83}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":83}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Adrenal insufficiency","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypophysitis","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Retinal detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":2,"numAtRisk":83}]},{"term":"Gastritis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Gastrointestinal disorder","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Gastrointestinal toxicity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Immune-mediated enterocolitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Intestinal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Intestinal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Segmental diverticular colitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Performance status decreased","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Bile duct stone","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hepatitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypersensitivity","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Abdominal sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"COVID-19 pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Clostridium difficile colitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Cystitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Device related bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Diverticulitis intestinal perforated","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Enterococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Herpes zoster","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Infectious pleural effusion","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Large intestine infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Lower respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Neutropenic sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Oral candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":11,"numAffected":10,"numAtRisk":83}]},{"term":"Pneumonia aspiration","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Pneumonia escherichia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Respiratory syncytial virus infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Staphylococcal infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Subperiosteal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Urosepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Humerus fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Thoracic vertebral fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Electrolyte imbalance","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypophagia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Osteolysis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Osteoporotic fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Pathological fracture","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Cancer fatigue","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Tumour compression","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Tumour haemorrhage","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Tumour pain","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Brain stem stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hyperaesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Lethargy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Occipital neuralgia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Peripheral sensorimotor neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Polyneuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Ureterolithiasis","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Acute pulmonary oedema","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Acute respiratory distress syndrome","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Immune-mediated lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Interstitial lung disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Malignant pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Pneumonitis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Dermatitis","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Drug eruption","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Lichenification","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Rash morbilliform","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Skin toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Euthanasia","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Hypovolaemic shock","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Orthostatic hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Superior vena cava occlusion","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":83}]},{"term":"Superior vena cava syndrome","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":35,"numAffected":30,"numAtRisk":85},{"groupId":"EG001","numEvents":13,"numAffected":12,"numAtRisk":83},{"groupId":"EG002","numEvents":30,"numAffected":28,"numAtRisk":83}]},{"term":"Hyperthyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Hypothyroidism","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":8,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":83}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":6,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":83}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":20,"numAtRisk":85},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":9,"numAtRisk":83}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":52,"numAffected":31,"numAtRisk":85},{"groupId":"EG001","numEvents":12,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":33,"numAffected":23,"numAtRisk":83}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":24,"numAtRisk":85},{"groupId":"EG001","numEvents":12,"numAffected":11,"numAtRisk":83},{"groupId":"EG002","numEvents":26,"numAffected":22,"numAtRisk":83}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":23,"numAffected":14,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":83}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":12,"numAtRisk":85},{"groupId":"EG001","numEvents":5,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":16,"numAffected":11,"numAtRisk":83}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":38,"numAffected":26,"numAtRisk":85},{"groupId":"EG001","numEvents":16,"numAffected":15,"numAtRisk":83},{"groupId":"EG002","numEvents":28,"numAffected":24,"numAtRisk":83}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":6,"numAffected":6,"numAtRisk":83}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":39,"numAffected":26,"numAtRisk":85},{"groupId":"EG001","numEvents":10,"numAffected":10,"numAtRisk":83},{"groupId":"EG002","numEvents":26,"numAffected":23,"numAtRisk":83}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":6,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":83}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":21,"numAffected":17,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":8,"numAtRisk":83}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":7,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":15,"numAffected":11,"numAtRisk":83}]},{"term":"COVID-19","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":13,"numAtRisk":85},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":83}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":6,"numAffected":6,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":83}]},{"term":"Amylase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":85},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":83}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Lipase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":85},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":25,"numAffected":14,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":24,"numAffected":15,"numAtRisk":83}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":16,"numAffected":14,"numAtRisk":85},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":83}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":21,"numAtRisk":85},{"groupId":"EG001","numEvents":11,"numAffected":11,"numAtRisk":83},{"groupId":"EG002","numEvents":25,"numAffected":19,"numAtRisk":83}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":6,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":3,"numAtRisk":83}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":83}]},{"term":"Hypomagnesaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":16,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":15,"numAffected":11,"numAtRisk":83}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":9,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":83}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":83}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":9,"numAffected":7,"numAtRisk":83}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":83}]},{"term":"Neuropathy peripheral","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":14,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":7,"numAtRisk":83}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":4,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":7,"numAffected":6,"numAtRisk":83}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":8,"numAffected":8,"numAtRisk":85},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":83}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":15,"numAffected":13,"numAtRisk":85},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":83},{"groupId":"EG002","numEvents":12,"numAffected":11,"numAtRisk":83}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":22,"numAffected":20,"numAtRisk":85},{"groupId":"EG001","numEvents":15,"numAffected":14,"numAtRisk":83},{"groupId":"EG002","numEvents":14,"numAffected":14,"numAtRisk":83}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":83}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":24,"numAffected":24,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":21,"numAffected":20,"numAtRisk":83}]},{"term":"Dry skin","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":9,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":83},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":83}]},{"term":"Eczema","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":7,"numAffected":7,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":83}]},{"term":"Nail disorder","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":6,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":4,"numAffected":4,"numAtRisk":83}]},{"term":"Nail toxicity","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":85},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":83}]},{"term":"Palmar-plantar erythrodysaesthesia syndrome","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":4,"numAffected":4,"numAtRisk":85},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":5,"numAtRisk":83}]},{"term":"Pruritus","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":51,"numAffected":31,"numAtRisk":85},{"groupId":"EG001","numEvents":21,"numAffected":17,"numAtRisk":83},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":83}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":28,"numAffected":22,"numAtRisk":85},{"groupId":"EG001","numEvents":17,"numAffected":15,"numAtRisk":83},{"groupId":"EG002","numEvents":8,"numAffected":7,"numAtRisk":83}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 27.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":5,"numAtRisk":85},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":83},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":83}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The investigator agrees to submit all manuscripts or abstracts to the Sponsor before submission. This allows the Sponsor to protect proprietary information and to provide comments."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme LLC","email":"ClinicalTrialsDisclosure@msd.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2022-12-19","uploadDate":"2025-07-30T12:07","filename":"Prot_SAP_001.pdf","size":1621789}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","submissionTracking":{"firstMcpInfo":{"postDateStruct":{"date":"2024-02-14","type":"ACTUAL"}}}},"conditionBrowseModule":{"meshes":[{"id":"D002289","term":"Carcinoma, Non-Small-Cell Lung"},{"id":"C565324","term":"Parkinson Disease 4, Autosomal Dominant Lewy Body"}],"ancestors":[{"id":"D002283","term":"Carcinoma, Bronchogenic"},{"id":"D001984","term":"Bronchial Neoplasms"},{"id":"D008175","term":"Lung Neoplasms"},{"id":"D012142","term":"Respiratory Tract Neoplasms"},{"id":"D013899","term":"Thoracic Neoplasms"},{"id":"D009371","term":"Neoplasms by Site"},{"id":"D009369","term":"Neoplasms"},{"id":"D008171","term":"Lung Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C582435","term":"pembrolizumab"},{"id":"D000077143","term":"Docetaxel"}],"ancestors":[{"id":"D043823","term":"Taxoids"},{"id":"D043822","term":"Cyclodecanes"},{"id":"D003516","term":"Cycloparaffins"},{"id":"D006840","term":"Hydrocarbons, Alicyclic"},{"id":"D006844","term":"Hydrocarbons, Cyclic"},{"id":"D006838","term":"Hydrocarbons"},{"id":"D009930","term":"Organic Chemicals"},{"id":"D004224","term":"Diterpenes"},{"id":"D013729","term":"Terpenes"}]}},"hasResults":true}